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Abstract: Juniper (Juniperus communis L.) is a northern coniferous plant generally used as a spice
and for nutritional purposes in foods and drinks. It was previously reported that juniper extract (JE)
affects p53 activity, cellular stress, and gene expression induced cell death in human neuroblastoma
cells. Therefore, the effects of juniper on p53 and Akt signaling was examined further in A549 lung,
22RV1 and DU145 prostate, and HepG2 liver cancer cells using Western blot, confocal microscopy,
and MTT analysis. We found that juniper simultaneously decreased cell viability, activated the p53
pathway, and inactivated the PI3K/Akt pathway. The p53 activation was associated with increased
nuclear p53 level. Akt was dephosphorylated, and its inactivation was associated with increased
levels of PHLPP1 and PHLPP2 phosphatases. Parallel increases of PARP suggest that JE decreased
cell viability by activating cell death. In addition, JE potentiated the effects of gemcitabine and
5-fluorouracil anticancer drugs. Thus, JE can activate cell death in different cancer cell lines through
p53 and Akt pathways.
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1. Introduction
Plant-derived phytochemicals have been widely studied as compounds for potential nutritional
and health-promoting strategies. Juniper (Juniperus communis L., Cupressaceae) is a northern coniferous
plant, and its berries have been used as a spice and for other purposes. Since juniper extract (JE)
contains many phenolic compounds, its potential physiological effects could be mediated through their
specific bioactive properties. In previous studies it has been found that JE influences diverse cellular
functions such as p53 activity, cellular stress, and gene expression, and furthermore induced cell death
in human neuroblastoma cells [1–3].
The p53 and PI3K/Akt signaling pathways are two key regulators of cell survival and
apoptosis, and their impaired functions are linked to many types of cancers [4]. The tumor
suppressor protein, p53 is active in the cytosol and nucleusand controls many cellular proteins
as well as gene expression [5,6]. p53 acts onprotein phosphorylation/dephosphorylation and gene
acetylation/deacetylation through direct cytosolic effects and nuclear translocation. The activity of Akt
is regulated by phosphatidylinositol-3-kinase (PI3K) as a part of the plasma membrane-linked second
messenger system [7,8]. The production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) by PI3K
leads to Akt phosphorylation. Akt is active in its phosphorylated form and can then also translocate
into the nucleus and control gene expression. Akt phosphorylation itself is regulated by PHLPP1 and
PHLPP2 phosphatases, and their impaired function is linked to cancer [9,10].
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Our aim was to study the molecular effects of Juniper berry extract on the regulation of cell death
in A549 lung cancer, 22RV1 and DU145 prostate cancer, and HepG2 liver cancer cells. The effects
of JE were specifically analyzed on the levels of cell viability, p53, pAkt, PHLPP1/2, pGsk3Ser9 and
PARP cleavage. In addition, the effects of JE were studied in combinations with two anticancer drugs,
gemcitabine and 5-fluorouracil.
2. Results
2.1. Juniper Extract Decreased Cell Viability in Several Cancer Cell Lines
The effects of JE on cell viability were analyzed in A549 non-small lung cancer, 22RV1 and
DU145 prostate cancer, and HepG2 hepatocellular carcinoma cell lines. We found that JE caused
a dose-dependent decrease in the cell viability with similar sensitivity across all these cancer cell
lines (Figure 1A and Figure 3A–C). In order to understand the causes of decreased cell viability, we
investigated whether these effects of JE were mediated by the activation of and mechanisms involved
in cell death (e.g., p53 and pAkt pathways).
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Figure 1. Juniper extract (JE) decreased cell viability, and induced the activation of P53 and apoptosis
in non-small lung cancer A549 cells. Cells were grown as described in the Materials and Methods
section, then starved for 24 h and incubated with JE for 24 hours. (A) Cell proliferation was estimated
by MTT-assay. (B) Cell lysates were analyzed for non-cleaved PARP (116 kDa) and cleaved PARP (85
kDa) by Western blotting. Cdk2 was used as a loading control. ( ) Cells ere fixed and stained for P53
and analyzed by confocal micr scopy (magnificatio : 63×). Signals were quantified and presented as
a perc ntage of control. (D) Cell lysates w re analyzed for P53 by Western blotting. Fig. B and D re
from the same experim nts, and the Cdk2 loa ing control is shown in (B). Data are presented s bars ±
standard deviation from three independent experiments. * Significantly different from control, p ≤ 0.05.
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2.2. Juniper Extract Activated the p53 Pathway in Parallel with the Inhibition of Cell Proliferation
Changes in p53 protein and PARP cleavage are often used to detect apoptosis, and the nuclear
localization of p53 is thought to be crucial for its proapoptotic properties [11]. Here, a dose-dependent
increase in the level of cleaved PARP and a decrease in uncleaved PARP was detected when the A549
cells were treated with JE (Figure 1B). Next, we also studied the effects of JE on p53 levels and nuclear
translocation in the non-small lung cancer A549 cells. We found that JE increased the level of p53
(Figure 1D) and induced the nuclear translocation of p53 (Figure 1C). The effects on the p53 and PARP
occurred in parallel with the decreased cell number, indicating an active role in cell death.
2.3. Juniper Extract Inactivated the Akt Pathway
It is known that Akt protects cells against apoptosis and hampers cancer therapy. The effect
of JE on the level of pAkt, an activated form of Akt, was studied in A549 cells. We found that JE
decreased the phosphorylation of Akt both at Serine 473 (Ser473) and Threonine 308 (Thr308) residues
in a dose-dependent manner (Figure 2A). The phosphorylation of the Akt downstream target pGsk3β
was inhibited, confirming that the JE decreased Akt-signaling (Figure 2A). Furthermore, JE seems to
regulate Akt through targeting its phosphatases, PHLPP1 and PHLPP2. JE increased the levels of
both phosphatases in a manner that correlated with the decreases of pAkt levels (Figure 2B). All these
results are in line with the decreased activity of Akt pathway and correspond to an increased level of
cell death pointing out an important role of Akt in the JE-induced cell death.
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Figure 2. JE inhibited Akt signaling pathway in A549 cells. Serum-starved A549 cells were treated with
JE for 24 h. (A) Cell lysates were analyzed for pAkt Ser473, pGSK3β Ser9, an pAkt Thr308 by Western
blotting. (B) Cell lysates were analyzed for PHLPP1 and PHLPP2 by Western blotting. (A,B) Cdk2
was used as loading control. Data are presented as bars ± standard deviation from three independent
experiments. * Significantly different from control, p ≤ 0.05.
2.4. Effects of Juniper Extract on Prostate and Hepatocellular Carcinoma Cells
The effects of J were studied further in prostate and hepatocellular cancer cells in order to
investigate the generality of the juniper-induced mechanisms and activation of cell death. It was
shown that the juniper treatment also increased the level of p53 in 22RV1 and DU145 prostate cancer
and HepG2 hepatocellular carcinoma cells (Figure 3D–F). In line with the anti-proliferative effects
(Figure 3A–C), JE decreased both pAkt and pGsk3β levels in 22RV1 and DU145 prostate cancer cells
and HepG2 hepatocellular carcinoma cells (Figure 3D–F).
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Serum-starved 22RV1, DU145, and HepG2 cells were treated with JE f r 24 h. (A–C) Cell p oliferation
was estimated by MTT assay. (D–F) Cell lysates were analyzed for pAkt Ser473, pGsk3β Ser9, and
P53 by Western blotting. Cdk2 was used as loading control. Data are presented as bars ± standard
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2.5. Juniper Extract Sensitized A549 Small Lung Cancer Cells to 5-Fluorouracil and Gemcitabine
The i teraction of JE-me iated echa isms with other cell death pathways was studied using
5-fluorouracil and gemcitabine, which have been used as anticancer drugs to treat in lung and pancreatic
cancers. To determine whether JE enhanced the efficiency of these compounds, we investigated the
effects of JE on cell viability and pAkt activation induced by 5-fluorouracil and gemcitabine in the
A549 cells. The decreases in the cell viability b 5-fluorouracil and gemcitabine alone were associated
with the decreases of pAkt and its downstream targ t pGsk3β (Figure 4A,B). When the cells were
treated with a combination of JE and anticancer drugs, the decreases of both pAkt and pGsk3β were
significantly potentiated, suggesting an interaction between 5-fluorouracil/gemcitabine and juniper on
the pAkt pathway.
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Figure 4. JE decreased pAkt and increased the effect of gemcitabine and 5-fluorouracil in A549 cells.
Serum-starved A549 cells were treated with JE and/or gemcitabine or 5-fluorouracil for 24 h. (A) Cell
proliferation was estimated by MTT assay. (B) Cell lysates were analyzed for pAkt Ser473 and pGSK3β
Ser9 by Western blotting. Cdk2 was used as loading control. Data are presented as bars ± standard
deviation from three independent experiments. *Significantly different from control, p ≤ 0.05.
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3. Discussion
Our data show that in low concentrations JE inhibited the phosphorylation of Akt in several cancer
cell lines. We also present results showing that juniper sensitized cells to cytostatic drugs. Recent
reports have suggested that the combined use of different drugs and natural products would improve
the efficiency of cancer therapy. For example, a potentiation of apoptosis was found in tumorigenic
cells with the combination of statins and etoposide, doxorubicin, or 5-fluorouracil [12,13]. Furthermore,
statin treatment increased the sensitivity to etoposide and 5-fluorouracil in A549 non-small lung
cancer cells [14]. It was suggested that the statin-induced sensitivity of apoptosis was mediated by
the inhibition of Akt phosphorylation and nuclear translocation. Similarly, increased apoptosis has
been found with the use of natural compounds and extracts. For example, the antitumor effects of
wine and rosemary treatments in cancer cells could be mediated by the combined action of various
compounds [15,16]. Earlier studies have shown in particular that the juniper berry extract activated
cell death by increasing p53 amount and nuclear translocation in the human SH-SY5Y neuroblastoma
cells [3]. In the present study, the anticancer effects of JE were seen in parallel with p53 activation and
pAkt inactivation, suggesting that the extract promotes cell death by regulating both of these pathways,
and possibly by other means as well.
A composition analysis of the JE identified several phenolic compounds which were further
classified to five main groups comprising flavones, flavonols, phenolic acids, flavanols, and
biflavonoids [1–3,17]. The most abundant phenolic compounds were rutin, apigenin, isoscutellarein,
hypolaetin, protocatechuic acid, and rutin. Here, the effective concentrations, dose dependence,
exposure times, and mechanisms were similar in all studied cancer cell lines, and were comparable
with our earlier findings in neuroblastoma cells. Accordingly, it was postulated that the JE, consisting
of a unique combination of phenolic compounds, targets cancer cells by specific apoptotic mechanisms.
The present results proved that the ability of JE to activate cell death is a more general effect, as
seen here in several types of cancer cells. In previous studies, JE was examined only in the human
SH-SY5Y neuroblastoma cells showing increased p53 activity and cell death [1,3]. In the present
study, the anticancer effects of JE were also found in A549 non-small lung cancer A549, 22RV1 and
DU145 prostate cancer, and HepG2 hepatocellular carcinoma cells. Interestingly, the effects of JE were
observed at remarkably small amounts with even 100–1000× lower concentrations than those used
for the respective compounds alone. The identified phenolic compounds were present at nanomolar
concentrations in JE treatments [3]. In general, when used alone, pure phenolic compounds have
been effective in decreasing cell viability or activating cell death at micromolar concentrations. This
has been shown, for example, for apigenin and curcumin in SH-SY5Y neuroblastoma cells [1,18,19]
or naringenin and quercetin in A549 small lung cancer cells [20,21]. Therefore, we propose that the
effects of JE were due to the potentiation, synergy, or both between several plant polyphenols through
common or different mechanisms.
The PI3K/Akt signaling pathway is frequently up-regulated in human cancers, and is induced
by cytostatic drugs. Our results show that JE inhibited the PI3K/Akt pathway by inhibiting its
phosphorylation. Threonine 308 and Serine 473 were dephosphorylated, resulting in an inactivation of
the Akt pathway, since the full activation of the Akt pathway is dependent on Akt phosphorylation
at Threonine 308 and the phosphorylation at Serine 473 helps to maintain the threonine-induced
activation. This inhibition could be mediated by JE-induced increases in the levels of PHLPP1 and
PHLPP2 phosphatases. These phosphatases are responsible for Akt dephosphorylation [10]. Both
PHLPP1 and PHLPP2 are tumor suppressors and downregulated in many cancers, thereby maintaining
Akt activity as well as promoting proliferation, growth, and survival. In addition, the JE decreased the
phosphorylation and activation of pGSK3β—a downstream target of Akt.
Another important regulator of cell death is the p53 tumor suppressor. The p53 is mutated or
inactivated in the majority of tumors. In the present study, the nuclear translocation of p53 and the
ratio of cleaved/intact PARP were induced in parallel, demonstrating the activation of cell death in
the A549 cells. The activation of p53 by the JE was also seen simultaneously with the inhibition of
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the Akt pathway in lung, hepatic, and prostate cancer cells. These and earlier results indicate that the
activation of cell death is mediated through combined effects by juniper polyphenols [1,3]. Similar
potentiation and interaction were also reported for statins sensitizing cancer cells to cytostatic drugs
such as doxorubicin, 5-fluorouracil, and gemcitabine [12–14], and plant extracts or compounds [1,15].
Interestingly JE was also able to potentiate the antitumor effects of 5-fluorouracil and gemcitabine in
A549 cells. The use of drug combinations may have synergistic therapeutic effects, improve selectivity,
and decrease side effects [22].
It is suggested that the p53 activation and Akt inhibition are cell-death-promoting mechanisms
of JE, and especially [23,24] together with cytostatic drugs, represent a potential model to study the
mechanisms of drug combinations in cancer cells. The exact mechanisms of the present results are still
unknown. Interactions of PI3K/Akt, p53, and PTEN activities in the regulation of apoptosis and drug
sensitivity have been found, for example, in non-small-cell lung cancer cell lines [23,24]. Plant extracts
and compounds have gained wide interest as a potential source for drug development against cancer
and other diseases [25]. Thus, JE seems to have several amplifying targets to activate p53, inactivate
the PI3K/Akt pathway, and reactivate cell death.
4. Materials and Methods
4.1. Plant Material and Reagents
Ripe and dried berries of juniper (Juniperus communis L.) cultivated for spice were commercially
obtained from Paulig Ltd, Finland (http://www.pauliggroup.com). The extracts of ground juniper
berries were prepared as described previously [17]. In brief, the extraction was performed by boiling
water during a three-hour hydrodistillation, resulting in the removal of volatile oils. The aqueous
extract was filtrated, freeze-dried, and stored at 4 ◦C. The yield of the extract was 422 mg/g of
ground berries. The anticancer drugs 5-fluorouracil (5-Fu) and gemcitabine were purchased from
Sigma-Aldrich (St. Louis, MO, USA) and Eli Lilly (Indianapolis, IN, USA), respectively.
4.2. Cell Culture
The human carcinoma cell lines A549, DU145, 22RV1, and HepG2 were purchased from ATCC
(Manassas, VA, USA). The A549 cell line is characterized by wild-type p53 and Akt genotype. DU145
has a mutated p53 and wild-type PTEN; 22RV1 has wild-type p53 and PTEN; and HepG2 has wild-type
p53 gene and PTEN. A549 and DU145 cells were grown in DMEM, with 10% inactivated fetal bovine
serum (FBS), and 1 mM sodium pyruvate. 22RV1 cells were grown in RPMI-1640 from Sigma-Aldrich
(St. Louis, MO, USA) supplemented with 10% FBS. HepG2 cells were grown in MEM, with Earl’s salts
and l-glutamine supplemented with 1 mmol/L of sodium pyruvate, nonessential amino acids, and
10% inactivated FBS. Media were supplemented with penicillin-streptomycin. Serum-starved cells
were cultured with medium supplemented with 0.1% serum for 24 h. DMSO was used to dissolve
5-fluorouracil and gemcitabine at the final concentration of <0.4% when added to the cells. No effect of
DMSO was observed.
4.3. Western Blotting
Cells were washed with PBS and lysed in IPB-7 buffer (triethanolamine-HCl (TEA), 1 M, pH 7.8;
NaCl, 5 M; sodium deoxycholate, 4%; Igepal CA-630 or Nonidet P-40, 10%) with inhibitors (1 mg/mL
phenylmethylsulfonyl fluoride, 0.1 mg/mL trypsin inhibitor, 1 mg/mL aprotinin, 1 mg/mL leupeptin,
1 mg/mL pepstatin, 1 mmol/L Na3–VO4, and 1 mmol/L NaF. Samples were subjected to SDS–PAGE
and blotted onto a PVDF membrane (Bio-Rad, Hercules, CA, USA). The protein bands were probed
using antibodies against Akt phosphorylated at residue Ser473 or Thr308, p53, PARP, and Cdk2 from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); pGSK3β Ser9 from Cell Signaling (Beverly,
MA, USA); PHLPP1 and PHLPP2 antibodies were from Bethyl Laboratories Inc. (Montgomery, TX,
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USA). Proteins were visualized with ECL procedure (Amersham Biosciences, Sweden). The results
were analyzed with NIH Image 1.62 software.
4.4. Confocal Microscopy
Cells were fixed with 4% formaldehyde, permeabilized with 0.2% Triton X-100 in 2% BSA buffer.
Immunostaining was performed using mouse monoclonal p53 antibody. Secondary antibodies were
conjugated with Alexa 488 (from ThermoFisher Scientific at NY, USA (Cat. Number: A11001). Cells
were analyzed with a Zeiss LSM 510 META confocal laser scanning microscope (Zeiss, Oberkochen,
Germany) equipped with a ×63 plan A oil-immersion lens. An argon laser was excited at 488 nm and
fluorescence images were recorded from 500 to 550 nm. The localization of indicated proteins was
measured by Zeiss LSM imaging software in multi-track mode.
4.5. MTT Assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide
(MTT) assay detecting the cellular mitochondrial capacity to convert MTT tetrazolium salt to formazan.
Cells were incubated with medium containing MTT (Sigma-Aldrich, St. Louis, MO, USA) for 4 h. The
cells were then lysed in DMSO. The absorbance was measured at 570–620 nm.
4.6. Statistical Analysis
Statistical analysis was conducted using the Student’s t-test. The data were presented as mean
± SD. Experiments were performed at least three times with different batches of cells. Results were
considered to be statistically significant at p ≤ 0.05.
5. Conclusions
In conclusion, the JE containing several plant phenolic compounds activated cell death in a
dose-dependent manner in A549 non-small lung cancer, HepG2 hepatocarcinoma, and 22RV1 and
DU145 prostate cancer cells through inhibition of PI3K/Akt and activation of p53 pathways. This
regulation was mediated by juniper’s effects on the Akt phosphorylation/dephosphorylation, PHLPP1
and PHLPP2, pGsk3 and intact/cleaved PARP, and p53 activation. The present results also showed
that the JE has cell death promoting effects in several types of cancer cells from different origins and
through specific target mechanisms.
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A549 Non-small lung cancer cell line
DMEM Dulbecco’s modified Eagle medium
DMSO Dimethyl sulfoxide
DU145 Prostate cancer cell line




PARP Poly (ADP-ribose) polymerase
PBS Phosphate-buffered saline
pGsk3Ser9 Phosphorylated glycogen synthase kinase-3
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